Strongbridge Biopharma plc announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced total revenue was USD 8.071 million compared to USD 5.684 million a year ago. Operating loss was USD 9.584 million compared to USD 16.930 million a year ago. Net loss was USD 3.159 million compared to USD 13.790 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.25 a year ago. Diluted loss per share from continuing operations was USD 0.18 compared to USD 0.31 a year ago. For the nine months, total revenue was USD 22.505 million compared to USD 16.106 million a year ago. Operating loss was USD 32.768 million compared to USD 50.458 million a year ago. Net loss was USD 33.129 million compared to USD 40.471 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.75 a year ago. Diluted loss per share from continuing operations was USD 0.6 compared to USD 0.91 a year ago.